河南羚锐制药股份有限公司董事会 专门委员会实施细则 董事会战略委员会实施细则 第一章 总则 第一条 为适应河南羚锐制药股份有限公司（以下简称"公司"）战略发展需要， 增强公司核心竞争力，确定公司发展规划，健全投资决策程序，加强决策科学性，提高 重大投资决策的效益和决策的质量，完善公司治理机构，根据《中华人民共和国公司法》、 《上市公司治理准则》、《河南羚锐制药股份有限公司章程》（以下简称"《公司章程》"） 及其他有关规定，公司特设立董事会战略委员会，并制定本实施细则。 第二条 董事会战略委员会是董事会按照股东会决议设立的专门工作机构，主要负 责对公司长期发展战略和重大投资决策进行研究并提出建议。 第二章 人员组成 第三条 战略委员会成员由三至七名董事组成，其中应至少包括一名独立董事。 第四条 战略委员会委员由董事长或者全体董事的三分之一提名，并由董事会选举 产生。 第五条 战略委员会设主任委员（召集人）一名，由公司董事长担任。 第六条 战略委员会任期与董事会任期一致，委员任期届满，连选可以连任。期间 如有委员不再担任公司董事职务，自动失去委员资格，并由委员会根据上述第三至第五 条规定补足委员人数。 第七条 战 ...

河南羚锐制药股份有限公司 控股子公司管理制度 第一章 总则 第一条 为加强对河南羚锐制药股份有限公司（以下简称"公司"或"本公司"） 控股子公司的管理，规范控股子公司经营行为，保护投资者合法权益，根据《中华人 民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证 券法》"）、《上海证券交易所股票上市规则》（以下简称"《上市规则》"）、《上海证券交 易所上市公司内部控制指引》及其他有关法律、法规和《河南羚锐制药股份有限公司 章程》（以下简称"《公司章程》"）的规定，制定本制度。 第二条 本制度所称控股子公司是指公司直接或间接持有其 50%以上的股权，或者 持股 50%以下但能够决定其董事会半数以上成员的组成，或者通过协议或其他安排能 够实际控制的具有独立法人资格的公司。 第三条 本制度适用于公司及公司控股子公司。 第二章 控股子公司管理的基本原则 第四条 公司作为出资人，依据中国证监会和上海证券交易所对上市公司规范运 作和法人治理结构的要求，以股东或控制人的身份行使对控股子公司的重大事项监督 管理，对投资企业依法享有投资收益、重大事项决策的权力。 第五条 公司对控股子公司进行统一 ...

证券简称：羚锐制药 证券代码：600285 公告编号：2025-032 号 河南羚锐制药股份有限公司 第九届董事会第十七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 河南羚锐制药股份有限公司（以下简称"公司"）第九届董事会第十七次会 议于 2025 年 10 月 22 日以通讯方式发出通知,并于 2025 年 10 月 28 日以通讯方 式召开。会议应到董事 9 名,实到 9 名。会议的召集和召开符合《中华人民共和 国公司法》和《河南羚锐制药股份有限公司章程》的规定。与会董事就会议议案 进行了审议、表决，形成了如下决议： 一、审议通过《2025 年第三季度报告》 本议案在提交公司董事会审议前已经公司第九届董事会审计委员会第十一 次会议审议通过。 内容详见上海证券交易所网站（http://www.sse.com.cn）公司同日披露的 《羚锐制药 2025 年第三季度报告》。 表决结果： 9 票赞成， 0 票反对， 0 票弃权 二、审议通过《关于取消监事会并修订<公司章程>的议案》 表决结果： 9 票赞成， 0 ...

Market Overview - On October 17, the traditional Chinese medicine sector declined by 0.99%, with Tianmu Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3839.76, down 1.95%, while the Shenzhen Component Index closed at 12688.94, down 3.04% [1] Stock Performance - Notable gainers in the traditional Chinese medicine sector included: - Weikang Pharmaceutical: closed at 23.39, up 3.54% with a trading volume of 84,100 shares and a turnover of 26.66 million [1] - Enwei Pharmaceutical: closed at 31.40, up 2.45% with a trading volume of 24,700 shares and a turnover of 78.62 million [1] - Zhongsheng Pharmaceutical: closed at 17.45, up 2.11% with a trading volume of 706,300 shares and a turnover of 1.244 billion [1] - Major decliners included: - Tianmu Pharmaceutical: closed at 18.40, down 5.30% with a trading volume of 120,100 shares and a turnover of 22 million [2] - Jilin Aodong: closed at 20.23, down 3.39% with a trading volume of 226,500 shares and a turnover of 465 million [2] Capital Flow - The traditional Chinese medicine sector experienced a net outflow of 736 million from institutional investors, while retail investors saw a net inflow of 582 million [2][3] - Key stocks with significant capital flow included: - Zhongsheng Pharmaceutical: net inflow of 72.58 million from institutional investors, but a net outflow of 131 million from retail investors [3] - Tianmu Pharmaceutical: net inflow of 19.99 million from institutional investors, with net outflows from both retail and speculative investors [3]

Core Viewpoint - The Chinese medicine sector shows resilience with the Chinese Medicine ETF (560080) rising by 0.28% despite market fluctuations, indicating strong investor interest and a net inflow of over 220 million yuan in the past 10 days [1][3]. Market Performance - The Chinese Medicine ETF (560080) has maintained a premium, closing with a premium rate of 0.14%, and has seen a total trading volume exceeding 1 billion yuan [1]. - Major stocks within the ETF, such as Dong'e Ejiao and Yunnan Baiyao, have shown positive performance, with Dong'e Ejiao increasing by over 1% [3][4]. Index Performance - The Chinese medicine index has experienced a negative return of -2.86% year-to-date, with a decline of 8.13% projected for 2024 [4]. - The index has shown a pattern of alternating performance, with three consecutive years of gains from 2019 to 2021, followed by three years of declines from 2016 to 2018 [4]. Valuation Metrics - The TTM price-to-earnings ratio for the Chinese Medicine ETF (560080) stands at 24.86, placing it at the 20.6% percentile of the past decade, suggesting a favorable valuation [6]. Financing and Investment Trends - Leveraged funds are increasingly utilizing the ETF for exposure to the higher-value Chinese medicine consumer sector, with the latest financing balance exceeding 91 million yuan, maintaining historical highs [7]. - The overall sentiment in the Chinese medicine sector is expected to improve, driven by stable market demand and accelerated innovation [9]. Future Outlook - The Chinese medicine sector is anticipated to benefit from innovation and transformation, with a focus on new product development and cost reductions in raw materials [9][10]. - The sector is positioned to leverage its advantages in preventive healthcare and as a complementary treatment alongside Western medicine [10]. Corporate Governance and Incentives - Recent corporate governance improvements and incentive plans in state-owned enterprises are expected to drive growth in the Chinese medicine sector, with companies like Huaren Sanjiu and Jiangzhong Pharmaceutical implementing effective incentive programs [11][12]. Dividend Yield - Several Chinese medicine companies are projected to have dividend yields exceeding 3% in 2024, with state-owned enterprises leading in this regard, indicating strong cash flow and shareholder returns [13][14].

Core Viewpoint - The announcement details the pledge of shares by the major shareholder, Lingrui Group, which holds a significant portion of Lingrui Pharmaceutical's stock, indicating a controlled risk situation without adverse effects on the company's operations or governance [2][3]. Group 1: Share Pledge Details - Lingrui Group holds 121,817,898 shares of Lingrui Pharmaceutical, accounting for 21.48% of the total share capital. After pledging 4,800,000 shares, the total pledged shares amount to 31,730,000, representing 26.05% of Lingrui Group's holdings and 5.59% of the company's total share capital [2]. - As of the announcement date, the total pledged shares by Lingrui Group and its concerted parties stand at 31,730,000, which is 5.59% of the company's total share capital [2]. Group 2: Impact Assessment - The share pledge by Lingrui Group is not expected to negatively impact the company's main business, financing credit, financing costs, or ongoing operational capabilities [3]. - The risk associated with the pledge is deemed controllable, and it will not lead to changes in the actual control of the company or adversely affect its production, governance, or independence [3]. - The company will continue to monitor the share pledge situation of its major shareholders and comply with relevant regulations for timely information disclosure [3].

（文章来源：证券日报） 证券日报网讯 9月25日晚间，羚锐制药发布公告称，河南羚锐集团有限公司持有公司股票121，817， 898股，占公司总股本的21.48%，本次质押4，800，000股。 ...

证券代码：600285 证券简称：羚锐制药 公告编号：2025-031 号 近日，公司接到羚锐集团股份质押的通知，羚锐集团将其持有的公司无限售 流通股 4,800,000 股质押给中信银行股份有限公司信阳分行，具体如下： 一、本次股份质押基本情况 1.本次股份质押基本情况 | | | | 是否为 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 是否 | | 限售股 | | | | | 占其 | 占公 | | | | 为控 | 本次质 | （如 | 是否 | 质押起 | 质押 | | 所持 | 司总 | 质押融资 | | 股东名称 | | | | 补充 | | 到期 | 质权人 | | | | | | 股股 | 押股数 | 是，注 | | 始日 | | | 股份 | 股本 | 资金用途 | | | | | | 质押 | | 日 | | | | | | | 东 | | 明限售 | | | | | 比例 | 比例 | | | | | | 类型） | | | | | | | | 1 | 河南 ...

Company Announcement - Lingrui Pharmaceutical announced on September 25 that Lingrui Group has pledged 4.8 million shares of the company to CITIC Bank's Xinyang branch [1] - Lingrui Group holds approximately 122 million shares of the company, accounting for 21.48% of the total share capital [1] - As of the date of the announcement, the total number of shares pledged by Lingrui Group and its concerted parties is 31.73 million, representing 5.59% of the company's total share capital [1]

Overview - The core viewpoint of the article highlights the growing demand for traditional Chinese medicine (TCM) transdermal patches due to their advantages such as no first-pass effect, minimal gastrointestinal damage, low toxicity, prolonged efficacy, and ease of use, particularly among populations that cannot take oral medications, like the elderly and children [1][4][8]. Market Size - The market size of TCM transdermal patches in China is projected to reach 14 billion yuan by 2024, accounting for 65.34% of the overall medicinal patch market [1][8]. Market Policies - The Chinese government has implemented various policies to support the development of the TCM industry, including measures to enhance scientific regulation, promote innovation, and improve healthcare quality from 2023 to 2025 [5][6]. Industry Chain - The upstream of the TCM transdermal patch industry includes suppliers of raw materials such as Chinese medicinal herbs, rubber, and various excipients, while the midstream consists of manufacturers of TCM transdermal patches, and the downstream includes medical institutions, retail pharmacies, and online pharmacies [6][7]. Sales Channels - Medical institutions are the primary sales channel for TCM transdermal patches, accounting for over 60% of sales. By the end of 2024, there will be approximately 1.092 million medical institutions in China, with a 2.0% year-on-year growth [7][8]. Competitive Landscape - The top five companies in the TCM transdermal patch market as of Q1 2025 include Qizheng Group, Yunnan Baiyao, Lingrui Pharmaceutical, Hillman Pharmaceutical, and China Resources Pharmaceutical, with Qizheng Group and Yunnan Baiyao leading the market [10][11]. Company Analysis - Qizheng Tibetan Medicine Co., Ltd. is a leading modern Tibetan medicine company with a revenue of 1.175 billion yuan in the first half of 2025, of which 824 million yuan (70.11%) comes from transdermal patch sales [12]. - Lingrui Pharmaceutical Co., Ltd. reported a total revenue of 2.099 billion yuan in the first half of 2025, with a gross profit of 1.707 billion yuan and a gross margin of 81.33% [13]. Development Trends - The demand for TCM transdermal patches is expected to grow due to the aging population and increasing prevalence of musculoskeletal and cardiovascular diseases. Additionally, the shift in health consciousness and the rise of online sales channels will further expand the market [13].